NCT05866783View on ClinicalTrials.gov

Serum Glycomics as Prognostic and Diagnostic Biomarkers of Disease Recurrence in Liver Transplant Recipients With Hepatocellular Carcinoma

RecruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

April 28, 2023

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2038

Conditions
Prognostic BiomarkerLiver TransplantationDiagnostic BiomarkerHepatocellular Carcinoma
Interventions
DIAGNOSTIC_TEST

HCCRecurrencePrognosticScore

Determination of serum glycomics pre-transplant using an optimal cutoff based on statistic modeling

DIAGNOSTIC_TEST

HCCRecurrenceDiagnosticScore

Determination of serum glycomics post-transplant using an optimal cutoff based on statistic modeling

Trial Locations (1)

9000

RECRUITING

Ghent University Hospital, Ghent

All Listed Sponsors
collaborator

University Hospital, Antwerp

OTHER

collaborator

Universitaire Ziekenhuizen KU Leuven

OTHER

collaborator

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

OTHER

lead

University Hospital, Ghent

OTHER